TELEFLEX INC TFX
Last close
138.36
2026-09-04
Market cap
$5.86B
2026-06-30 share count
52-week range
100.18 - 145.00
Valuation FY2025 figures against the last close
P/S2.9x
P/E—
P/FCF4,054.4x
EV/EBITDA46.6x
Dividend yield1.0%
Diluted EPS-20.25
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.99B | $1.70B | $1.71B | $2.79B | $2.81B | $2.54B | $2.60B | $2.45B | $2.15B | $1.87B |
| Cost of revenue | $872.0M | $662.2M | $672.3M | $1.26B | $1.26B | $1.21B | $1.19B | $1.15B | $974.5M | $871.8M |
| Gross profit | $1.12B | $1.04B | $1.04B | $1.53B | $1.55B | $1.32B | $1.41B | $1.30B | $1.17B | $996.2M |
| R&D | $144.8M | $109.0M | $113.6M | $153.8M | $130.8M | $119.7M | $113.9M | $106.2M | $84.8M | $58.6M |
| SG&A | $720.2M | $674.5M | $622.7M | $863.7M | $860.1M | $743.6M | $851.8M | $797.1M | $700.0M | $563.3M |
| Operating income | $118.4M | $103.7M | $258.7M | $499.7M | $628.1M | $423.1M | $427.3M | $321.7M | $372.3M | $319.5M |
| Interest expense | $100.2M | $83.5M | $85.0M | $54.3M | $57.0M | $66.5M | $80.3M | $103.0M | $82.5M | $54.9M |
| Pre-tax income | $24.6M | $26.3M | $185.4M | $445.9M | $559.5M | $357.7M | $339.9M | $219.6M | $284.9M | $245.7M |
| Income tax | $34.0M | $30.9M | $41.9M | $83.0M | $74.3M | $21.9M | $122.1M | $23.2M | $129.6M | $8.1M |
| Net income | -$905.6M | $70.2M | $357.6M | $363.1M | $485.4M | $335.3M | $461.5M | $200.8M | $152.5M | $237.4M |
| EPS, basic | -20.30 | 1.49 | 7.58 | 7.74 | 10.38 | 7.21 | 9.99 | 4.39 | 3.39 | 5.48 |
| EPS, diluted | -20.25 | 1.48 | 7.53 | 7.68 | 10.23 | 7.09 | 9.80 | 4.29 | 3.27 | 4.98 |
| Shares, diluted (wtd. avg.) | $44.7M | $47.1M | $47.3M | $47.3M | $47.4M | $47.3M | $47.1M | $46.8M | $46.7M | $47.6M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $378.6M | $247.9M | $222.8M | $292.0M | $445.1M | $375.9M | $301.1M | $357.2M | $333.6M | $543.8M |
| Receivables | $345.6M | $226.7M | $443.5M | $408.8M | $383.6M | $395.1M | $418.7M | $366.3M | $345.9M | $272.0M |
| Inventory | $404.4M | $306.8M | $626.2M | $578.5M | $477.6M | $513.2M | $476.6M | $427.8M | $395.7M | $316.2M |
| Total current assets | $1.94B | $1.47B | $1.41B | $1.41B | $1.43B | $1.42B | $1.31B | $1.24B | $1.13B | $1.18B |
| Property, plant and equipment | $498.3M | $308.5M | $479.9M | $447.2M | $443.8M | $473.9M | $430.7M | $432.8M | $383.0M | $302.9M |
| Goodwill | $2.31B | $1.99B | $2.91B | $2.54B | $2.50B | $2.59B | $2.25B | $2.25B | $2.24B | $1.28B |
| Other intangibles | $1.52B | $1.35B | $2.50B | $2.31B | $2.29B | $2.52B | $2.16B | $2.33B | $2.38B | $1.09B |
| Total assets | $6.95B | $7.10B | $7.53B | $6.93B | $6.87B | $7.15B | $6.31B | $6.28B | $6.18B | $3.89B |
| Accounts payable | $130.2M | $97.9M | $132.2M | $126.8M | $118.2M | $102.5M | $102.9M | $106.7M | $92.0M | $69.4M |
| Short-term debt | $100.0M | $100.0M | $87.5M | $87.5M | $110.0M | $100.5M | $50.0M | $86.6M | $86.6M | $183.1M |
| Total current liabilities | $762.0M | $649.4M | $606.7M | $581.5M | $680.1M | $540.0M | $563.1M | $582.5M | $483.9M | $427.6M |
| Long-term debt | $2.54B | $1.56B | $1.73B | $1.62B | $1.74B | $2.38B | $1.86B | $2.07B | $2.16B | $850.3M |
| Total liabilities | $3.82B | $2.82B | $3.09B | $2.91B | $3.12B | $3.82B | $3.33B | $3.74B | $3.75B | $1.75B |
| Retained earnings | $3.15B | $4.12B | $4.11B | $3.82B | $3.52B | $3.10B | $2.82B | $2.43B | $2.29B | $2.19B |
| Total equity | $3.12B | $4.28B | $4.44B | $4.02B | $3.75B | $3.34B | $2.98B | $2.54B | $2.43B | $2.14B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $96.7M | $301.9M | $206.1M | $342.8M | $652.1M | $437.1M | $437.1M | $435.1M | $426.3M | $410.6M |
| Depreciation and amortisation | $56.1M | $52.8M | $45.5M | $66.5M | $71.8M | $68.6M | $64.1M | $60.5M | $56.5M | $54.4M |
| Stock-based compensation | $25.7M | $26.0M | $27.3M | $27.2M | $22.9M | $20.7M | $26.9M | $22.4M | $19.4M | $16.9M |
| Capital expenditure | $95.2M | $90.4M | $46.4M | $79.2M | $71.6M | $90.7M | $102.7M | $80.8M | $70.9M | $53.1M |
| Investing cash flow | -$812.7M | -$63.4M | $27.3M | -$259.4M | $156.7M | -$837.8M | -$73.5M | -$196.4M | -$1.83B | -$57.0M |
| Financing cash flow | $611.5M | -$421.9M | $38.5M | -$217.5M | -$715.8M | $455.2M | -$418.8M | -$206.4M | $1.14B | -$118.7M |
| Dividends paid | $60.3M | $63.5M | $63.9M | $63.8M | $63.6M | $63.2M | $62.8M | $62.2M | $61.2M | $59.0M |
| Buybacks | $300.0M | $200.0M | $0 | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000096943-26-000039.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |